Wall Street analysts expect Acasti Pharma Inc (NASDAQ:ACST) to post earnings of ($0.08) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Acasti Pharma’s earnings, with estimates ranging from ($0.11) to ($0.05). Acasti Pharma posted earnings per share of ($0.96) in the same quarter last year, which suggests a positive year-over-year growth rate of 91.7%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Acasti Pharma will report full year earnings of ($0.36) per share for the current year, with EPS estimates ranging from ($0.54) to ($0.17). For the next financial year, analysts expect that the firm will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.26) to ($0.14). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Acasti Pharma.

Acasti Pharma (NASDAQ:ACST) last released its earnings results on Thursday, February 14th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03.

A number of analysts recently commented on the company. Zacks Investment Research upgraded Acasti Pharma from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research report on Monday, December 17th. ValuEngine lowered Acasti Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd.

Acasti Pharma stock traded down $0.03 during midday trading on Thursday, reaching $1.05. The company’s stock had a trading volume of 472,400 shares, compared to its average volume of 359,848. Acasti Pharma has a fifty-two week low of $0.43 and a fifty-two week high of $1.80. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.45 and a current ratio of 3.45. The company has a market cap of $84.38 million, a P/E ratio of -1.38 and a beta of 1.23.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can increased its position in Acasti Pharma by 60.3% in the 4th quarter. Bank of Montreal Can now owns 247,612 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 93,185 shares during the last quarter. K.J. Harrison & Partners Inc bought a new stake in shares of Acasti Pharma in the 4th quarter worth approximately $28,000. Geode Capital Management LLC bought a new position in shares of Acasti Pharma during the 4th quarter worth approximately $40,000. Pura Vida Investments LLC acquired a new stake in Acasti Pharma during the 4th quarter valued at $157,000. Finally, Perceptive Advisors LLC acquired a new stake in Acasti Pharma during the 4th quarter valued at $1,480,000. 3.47% of the stock is owned by institutional investors and hedge funds.

Acasti Pharma Company Profile

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Featured Article: Understanding Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Acasti Pharma (ACST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.